Polycythemia Vera 
Welcome,         Profile    Billing    Logout  

116 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Polycythemia Vera
PV, NCT06290765: Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Low-Risk Polycythemia Vera

Not yet recruiting
4
110
NA
Ropeginterferon alfa-2b, P1101, Phlebotomy
PharmaEssentia
Polycythemia Vera, Myeloproliferative Neoplasm
12/25
02/27
HU-F-AIM, NCT05853458: Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors

Recruiting
4
300
Europe
Hydroxyurea
Novartis Pharmaceuticals
Polycythemia Vera
09/24
12/26
NCT02386800 / 2014-003527-22: CINC424A2X01B Rollover Protocol

Recruiting
4
356
Europe, Japan, RoW
ruxolitinib, INC424, Jakavi, panobinostat, LBH589, Farydak
Novartis Pharmaceuticals
Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia
09/27
09/27
Molecular responses in patients with PV/ET treated with different doses intensities of pegylated interferon α-2b, ChiCTR2200065811: A multicenter, retrospective, prospective, non-intervention study was conducted to observe the molecular responses in patients with polycythemia vera and essential thrombocythemia with JAK2V617F mutation treated with pegylated interferon α-2b at different dose intensities

Recruiting
4
200
 
N/A
Department of Hematology, Peking Union Medical College Hospital; Peking Union College Hospital, Xiamen Tebao Biological Engineering Co., LTD
myeloproliferative neoplasms
 
 
2018-001908-11: Ruxolitinib versus hydroxycarbamide or interferon as first line therapy in high risk polcythemia vera - a phase III randomised trial

Not yet recruiting
3
586
Europe
JAKAVI(r), HYDREA(r), Tablet, Capsule, JAKAVI(r), HYDREA(r)
UNIVERSITY OF BIRMINGHAM, PHRC
Myeloproliferative neoplasm (MPN), specifically Polycythaemia Vera, Disease of the bone marrow in which excess red blood cells are produced, Diseases [C] - Cancer [C04]
 
 
ACTRN12609000046202: A large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events In patients with Polycythemia Vera (PV)

Recruiting
3
1000
 
Consorzio Mario Negri Sud, Agenzia Italiana del Farmaco
polycythemia vera, To assess the benefit/risk profile of cytoreductive therapy with phlebotomy and/or hydroxyurea (HU) aimed at maintaining hematocrit (HCT) < 45% Vs. maintaining HCT in the range of 45-50% in patients with PV treated at the best of recommended therapies (e.g., low dose of aspirin when indicated and adequated control of standard cardiovascular risk factors)
 
 
ACTRN12614000740695: Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (PAC326)

Recruiting
3
300
 
Cell Therapeutics Inc., Cell Therapeutics Inc.
Primary Myelofibrosis
 
 
2011-001919-31: DALIAH A Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Ph-negative Chronic Myeloid Neoplasias - A National Randomized Prospective Study With Focus on Efficacy, Toxicity and Quality of Life DALIAH Dansk Studie af Lav-dosis Interferon Alpha vs Hydroxyurea i Behandlingen af Ph-Negative kroniske myeloproliferative neoplasier “Et Nationalt Randomiseret Prospektivt Kvalitetssikringsstudie med Særlig Fokus på Effekt, Toxicitet og Livskvalitet”

Ongoing
3
200
Europe
Suspension for injection in pre-filled pen, Capsule, hard, Pegasys, PegIntron, Hydrea
Roskilde sygehus, Swedish Orphan, Ellen og Aage Fausbølls Helsefond af 1975, Fonden til lægevidenskabens Fremme, Odense Universitetshospitals forskningspulje, Region Sjællands og Region Syddanmarks fælles forskningspulje
Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Chronic myeloid neoplasms Essential thrombocythemia Polycythemia vera primary myelofibrosis Kroniske myeloide neoplasier Essential thrombocythemia Polycythemia vera primary myelofibrosis, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2010-019501-41: A randomized study comparing two drugs: hydroxyurea and Pegylated Interferon Alfa-2a, in an open label clinical trial in two independent diseases: (1) high risk polycythaemia vera and (2) high risk essential thrombocythaemia.

Ongoing
3
95
Europe
peginterferon alfa-2a, Hydroxyurea, Pegasys, Pegasys, Hydroxyurea, Pegasys, Hydroxyurea
CONSORZIO MARIO NEGRI SUD, Consorzio Mario Negri Sud, Myeloproliferative Disease Research Consortium (MPD-RC), Myeloproliferative Disorders Research Consortium, National Cancer Institute, F.Hoffmann-La Roche, Cancer Research UK, MPD-RC
The myeloproliferative disorders essential thrombocythaemia (ET) and polycythaemia vera (PV).
 
 
2012-004239-21: A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia)

Ongoing
3
75
Europe
pacritinib, SB1518,
CTI BioPharma Corp., CELL THERAPEUTICS INC., CTI BioPharma Corp., Cell Therapeutics Inc
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
 
 
2013-004000-19: A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia) in patients with a low platelet count

Ongoing
3
50
Europe
pacritinib, SB1518,
CTI BioPharma Corp., Cell Therapeutics, Inc., CTI BioPharma Corp., Cell Therapeutics, Inc.
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Thrombocytopenia
 
 
2020-000111-69: PACIFICA Phase 3: A Study of Pacritinib Versus Physician’s Choice in Patients with Myelofibrosis

Ongoing
3
348
Europe, RoW
Pacritinib, Ruxolitinib, Hydroxyurea, methylprednisolone, Dexamethasone, Prednisone, Capsule, hard, Tablet, Soluble tablet
CTI BioPharma Corp., CTI BioPharma Corp.
Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL), Post polycythaemia vera myelofibrosis, Primary or Secondary Myelofibrosis (MF), Diseases [C] - Cardiovascular Diseases [C14]
 
 
2020-004652-15: AVAJAK: Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myelo-proliferative neoplasms AVAJAK: Apixaban/rivaroxaban Versus Aspirine en prévention primaire des complications thromboemboliques des néoplasies myéloprolifératives mutées pour JAK2V617F

Not yet recruiting
3
1340
Europe
Tablet, Gastro-resistant capsule, Eliquis, Xarelto, Aspirine Protec
CHRU de Brest, PHRC-K
Myelo-proliferative neoplasms including essential thrombocythemia, Polycythemia Vera, Prefibrotic myelofibrosis Néoplasies myéloprolifératives incluant les thrombocytémies essentielles, polyglobulies de Vaquez et pyélofibroses préfibrotiques, Myelo-proliferative neoplasms including essential thrombocythemia, Polycythemia Vera, Prefibrotic myelofibrosis Néoplasies myéloprolifératives incluant les thrombocytémies essentielles, polyglobulies de Vaquez et pyélofibroses préfibrotiques, Diseases [C] - Cancer [C04]
 
 
FREEDOM, NCT03755518: A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Completed
3
38
Canada, US
FEDRATINIB
Celgene, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
11/21
11/23
MOMENTUM, NCT04173494 / 2019-000583-18: A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants

Checkmark New data from MOMENTUM trial in myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: New data from MOMENTUM trial in myelofibrosis at ASH 2022
Checkmark Results for symptomatic and anemic 2L Myelofibrosis based on MOMENTUM study at ASCO 2022
May 2022 - May 2022: Results for symptomatic and anemic 2L Myelofibrosis based on MOMENTUM study at ASCO 2022
Checkmark Data for myelofibrosis at ASCO 2022 based on from MOMENTUM trial
More
Completed
3
195
Europe, Canada, US, RoW
Momelotinib, MMB, GS-0387, CYT387, Placebo to match danazol, Danazol, Danocrine, Placebo to match momelotinib
Sierra Oncology LLC - a GSK company
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
12/21
12/22
FREEDOM2, NCT03952039 / 2018-003411-21: An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Active, not recruiting
3
202
Europe, RoW
FEDRATINIB, Best Available Therapy (BAT)
Celgene, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Primary Myelofibrosis, Post-Polycythemia Vera, Myelofibrosis
12/22
06/25
LIMBER-313, NCT04551066: To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

Active, not recruiting
3
252
Europe, Japan, US, RoW
parsaclisib, INCB050465, ruxolitinib, Jakafi, Jakavi, placebo
Incyte Corporation
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
08/23
07/24
LIMBER-304, NCT04551053: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Oct 2023 - Dec 2023: Data from LIMBER-304 trial n combination with ruxolitinib for myelofibrosis
Active, not recruiting
3
177
Europe, Japan, US, RoW
parsaclisib, INCB050465, ruxolitinib, Jakafi, Jakavi, placebo
Incyte Corporation
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
08/23
07/24
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Calendar Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Exclusivity expiry in US
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT04816578: To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Recruiting
3
440
US
parsaclisib, INCB050465, ruxolitinib, Jakafi, Jakavi, placebo
Incyte Corporation
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
09/23
02/26
NCT04816565: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Not yet recruiting
3
212
Europe, US
parsaclisib, INCB050465, ruxolitinib, Jakafi, Jakavi, placebo
Incyte Corporation
Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
11/23
12/23
NCT05481151: A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

Recruiting
3
100
Canada, US
P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)
PharmaEssentia
Polycythemia Vera
01/24
12/25
VERIFY, NCT05210790 / 2021-004732-29: A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Completion of enrollment of P3 VERIFY trial for PCV
Recruiting
3
250
Europe, Canada, US, RoW
Placebo, Rusfertide
Protagonist Therapeutics, Inc.
Polycythemia Vera
02/25
06/25
MK-3543-017, NCT06351631: A Study to Evaluate Safety and Efficacy of Bomedemstat

Recruiting
3
400
Europe, RoW
Bomedemstat, MK-3543, IMG-7289
Merck Sharp & Dohme LLC
Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
12/34
12/34
NCT06002490: A Study to Evaluate P1101 in Japanese PV Patients

Recruiting
3
20
Japan
P1101, Ropeginterferon alfa-2b, Low-dose aspirin, Low-doaw Acetylsalicylic acid, Phlebotomy
PharmaEssentia Japan K.K.
Polycythemia Vera (PV)
07/24
07/24
NCT04655092: Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

Recruiting
3
67
Japan
P1101 (Ropeginterferon alfa-2b)
PharmaEssentia Japan K.K.
Polycythemia Vera (PV)
10/24
10/24
INDEPENDENCE, NCT04717414 / 2020-000607-36: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Calendar Jan 2025 - Dec 2025: Data from INDEPENDENCE trial for myelofibrosis
Recruiting
3
309
Europe, Canada, Japan, US, RoW
ACE-536, Luspatercept, BMS-986346, Placebo
Celgene
Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Anemia
03/25
08/25
PACIFICA, NCT03165734 / 2017-001772-28: A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Calendar May 2026 - Sep 2026: Data from PACIFICA trial for myelofibrosis
Recruiting
3
399
Europe, Canada, US, RoW
Pacritinib, Physician's Choice medications, corticosteroids, hydroxyurea, danazol, low-dose ruxolitinib
CTI BioPharma, PSI CRO
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
06/25
12/25
THRIVE, NCT06033586: Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

Enrolling by invitation
3
50
US
Open-label rusfertide
Protagonist Therapeutics, Inc.
Polycythemia Vera
04/26
04/27
GIV-IN PV, NCT06093672: Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

Recruiting
3
220
Europe, US, RoW
Givinostat Hydrochloride, Hydroxy Urea
Italfarmaco
Polycythemia Vera
07/26
07/26
MITHRIDATE, NCT04116502: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

Recruiting
3
586
Europe
Ruxolitinib, Jakavi®, Hydroxycarbamide, Hydroxyurea, Interferon-Alpha, Interferon, alpha interferon, Intron® A, Roferon® A
University of Birmingham, Novartis, MPN Voice, National Cancer Institute, France
Polycythemia Vera
08/26
02/28
AVAJAK, NCT05198960: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Recruiting
3
1308
Europe
Direct Oral Anticoagulants, Low-dose aspirin
University Hospital, Brest
Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients
07/27
07/27
BOREAS, NCT03662126 / 2018-001671-21: KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Recruiting
2/3
385
Europe, Canada, US, RoW
KRT-232, Best Available Therapy (BAT)
Kartos Therapeutics, Inc., Kartos Therapeutics, Inc.
Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
12/23
12/25
NCT03669965 / 2018-001672-38: KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Active, not recruiting
2a/2b
20
Europe, US
KRT-232, Ruxolitinib
Kartos Therapeutics, Inc.
Polycythemia Vera
04/22
10/22
NCT01242709: Study in Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Not yet recruiting
2
54
US
AB0024
Arresto Biosciences, Inc.
Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
12/11
12/13
2010-019500-23: Therapy with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera or Essential Thrombocythemia who are Either Hydroxyurea Resistant or Intolerant Or have had Abdominal Vein Thrombosis. Terapia con l'interferone Alfa-2a (PEGASYS) Peghilato per i pazienti con Policitemia Vera o Trombocitemia Essenziale che sono resistenti o intolleranti al trattamento con Hydroxyurea o che hanno avuto una trombosi della vena spalcnica.

Ongoing
2
188
Europe
Solution for injection, Peginterferon PFS
CONSORZIO MARIO NEGRI SUD, Myeloproliferative Disorders-Research Consortium
High risk polycythemia vera and high risk essential thrombocythemia Policitemia Vera (PV) ad alto rischio o Trombocitemia Essenziale (ET) ad alto rischio, polycythemia vera or essential thrombocythemia Policitemia Vera o Tromcitemia Essenziale, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01534767: Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Recruiting
2
19
US
sirolimus, AY 22989, Rapamune, rapamycin, SLM, tacrolimus, FK 506, Prograf, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, laboratory biomarker analysis, flow cytometry
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia, Waldenstrom Macroglobulinemia
06/13
10/13
2012-005010-19: Exploring the potential of adding the drug Ruxolitinib to the standard reduced intensity (lower strength) chemotherapy regimen prior to bone marrow transplant in patients with myelofibrosis.

Ongoing
2
86
Europe
Ruxolitinib (INC424), Tablet, Jakavi
Consorzio Mario Negri Sud, National Cancer Institute, Leukaemia & Lymphoma Research
Primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as myelofibrosis (MF), MF is a form of bone marrow cancer in which bone marrow tissue develops in abnormal sites because the bone marrow itself undergoes fibrosis or scarring., Diseases [C] - Cancer [C04]
 
 
2007-007335-99: A Phase II Study of Erlotinib in Patients with Polycythaemia Vera and Essential Thrombocythemia

Ongoing
2
10
Europe
Tarceva, Tarceva
Herlev Hospital, Dept. of Haematology (L121)
Polycythaemia Vera & Essential Thrombocythaemia
 
 
2011-005279-18: A study of best available therapy versus Ruxolitinib in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide (standard therapy)

Ongoing
2
306
Europe
Ruxolitinib, INC424,
University of Birmingham
Polycythaemia veraEssential Thrombocythaemia
 
 
2013-003295-12: Kombinationsbehandling med Interferon og JAK1-2 Hæmmer i behandlingen af Ph-Negativ Myeloprolifertiv Cancer

Ongoing
2
50
Europe
Jakavi, Jakavi, Pegasys 135 microgram, PegIntron 50 microgram, Jakavi, Pegasys 135 microgram, PegIntron 50 microgram
Roskilde University Hospital, Novartis
Polycythemia vera Hyperproliferativ myelofibrosis, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2012-003276-39: Investigation of the value of bonemarrow stimulation in the diagnostic proces of patients with excess red/white bloodcells and platelets. Undersøgelse af værdien af stimulering af knoglemarven i udredningen af patienter med for mange blodceller (røde, hvide/blodplader).

Ongoing
2
50
Europe
ferro duretter, Neupogen, Ferro Duretter, Neupogen, Ferro Duretter, Neupogen
Hæmatologisk afdeling, Roskilde Sygehus, Region Sjælland, Region Sjælland
Polycythemia Vera Essential thrombocytosis Polycythemia Vera Essential thrombocytosis
 
 
2016-001406-42: Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.

Ongoing
2
100
Europe
Atorvastatin, Zoledronic acid, Tablet, Concentrate for solution for injection/infusion
Hæmatologisk Afdeling, Sjælland Sygehus, Roskilde, Hæmatologisk Afdeling, Sjælland Sygehus, Roskilde
The Philadelphia-negative chronic myeloproliferative neoplasms: Essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis., Chronic bloodcancer, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2018-004150-13: Combination Therapy with Interferon-Alpha2a and Ruxolitinibin Newly Diagnosed Patients with Polycythemia Vera.A Danish Safety and Efficacy Study.

Not yet recruiting
2
25
Europe
Tablet, Injection, Jakavi, Pegasys
Zealand University hospital, Novartis
Polycythemia Vera, Polycythemia Vera, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-002042-32: A phase II study of CPX-351 monotherapy in Acute Myeloid Leukemia secondary to Myeloproliferative neoplams Étude de phase II d’une monothérapie par cpx-351 dans les leucémies aiguës secondaires à un syndrome myéloprolifératif

Not yet recruiting
2
42
Europe
Vyxeos, CPX-351, Powder for concentrate for solution for injection/infusion, CPX-351, VYXEOS
FILO, FILO, JAZZ PHARMACEUTICAL
newly secondary AML according to WHO 2016 classification following an antecedent of Myeloproliferative Neoplasm including Essential Thrombocythemia (ET), Polycythemia Vera (PV), primary or secondary Myelofibrosis Premier diagnostic de LAM secondaires selon la classification OMS 2016 avec un antécédent de néoplasie myeloproliferative (NMP) incluant une thrombocytémie essentielle (TE), une polyglobulie primitive (PV), une myélofibrose primitive ou secondaire, newly secondary AML following an antecedent of Myeloproliferative Neoplasm including Essential Thrombocythemia (ET), Polycythemia Vera (PV), primary or secondary Myelofibrosis Premier diagnostic de LAM secondaires selon la classification OMS 2016 avec un antécédent de néoplasie myeloproliferative (NMP) incluant une TE, une PV, ou une myélofibrose primitive ou secondaire, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03003325 / 2015-004717-25: The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV

Completed
2
127
Europe
AOP2014, Pegylated-Proline-Interferon α-2b, P1101, Phlebotomies, blood removing, ASA, Acetylsalicylic Acid
Fondazione per la Ricerca Ospedale Maggiore, AOP Orphan Pharmaceuticals AG
Polycythemia Vera
03/22
03/23
ZGJAK006, NCT04217993: Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Completed
2
51
RoW
Jaktinib hydrochloride tablets, Jaktinib
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
08/22
08/22
NCT03333486: Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Active, not recruiting
2
31
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, peripheral stem cell support, Peripheral Stem Cell Transplant, peripheral stem cell transplantation, Total-Body Irradiation, TOTAL BODY IRRADIATION, Whole-Body Irradiation
Roswell Park Cancer Institute
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
08/23
08/24
NCT05485948: A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

Active, not recruiting
2
49
RoW
Ropeginterferon alfa-2b, BESREMI
PharmaEssentia
Polycythemia Vera
09/22
05/25
PACIFIC, NCT04767802: PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit

Hourglass Dec 2023 - Dec 2023 : Data from PACIFIC trial for polycythemia vera at ASH 2023
Completed
2
20
RoW
PTG-300, Rusfertide
Protagonist Therapeutics, Inc.
Polycythemia Vera
03/23
03/23
2022-003009-31: Atorvastatin for patients with Philadelphia-negative chronic myeloproliferative neoplasms - Essential thrombocythemia, polycythemia vera and prefibrotic myelofibrosis Atorvastatin til patienter med de Philadelphia-negative kronisk myeloproliferative neoplasier - essentiel trombocytose, polycythemia vera og prefibrotisk myelofibrose

Not yet recruiting
2
40
Europe
Atorvastatin, Coated tablet
Zealand University Hospital, dept. of Haematology, Region Zealand
Essential thrombocythemia, Polycythemia vera, prefibrotic myelofibrosis, blood cancer, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
LIMBER-213, NCT04821791: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy.

Recruiting
2
60
US
itacitinib, INCB039110
Incyte Corporation
Myelofibrosis, Polycythemia Vera, Thrombocythemia
02/23
02/23
NCT03289910: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Active, not recruiting
2
25
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Topotecan, Hycamptamine, Topotecan Lactone, Topotecan Hydrochloride, Evotopin, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Polycythemia Vera, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
05/23
12/24
NCT04644211: Ruxolitinib in Thrombocythemia and Polycythemia Vera

Recruiting
2
60
US
Ruxolitinib, Jakafi
Massachusetts General Hospital, Incyte Corporation
Essential Thrombocythemia, Polycythemia Vera
12/24
12/24
2020-003123-42: A study evaluating safety, tolerability and efficacy of Itacitinib in participants with primary or secondary Myelofibrosis

Not yet recruiting
2
73
Europe
Itacitinib, INCB039110, Tablet
Incyte Corporation, INCYTE CORPORATION, Incyte Corporation
Primary Myelofibrosis or Secondary Myelofibrosis, Primary Myelofibrosis or Secondary Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
NCT04629508: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Completed
2
4
Europe, US
itacitinib, INCB039110
Incyte Corporation
Myelofibrosis, Polycythemia Vera, Thrombocythemia
08/23
08/23
AIRPORT-MPN, NCT04243122: Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

Completed
2
44
Canada
Apixaban 2.5 MG Oral Tablet [ELIQUIS], Eliquis, Aspirin 81 mg, Acetylsalicylic acid
Ottawa Hospital Research Institute, Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, the Association médicale universitaire de l'Hôpital Montfort (AMUHM), Canadian Hematology Society
Myeloproliferative Neoplasm (MPN), Essential Thrombocythemia (ET), JAK2 Mutation, Polycythemia Vera (PV), Primary Myelofibrosis, Venous Thromboembolism (VTE)
10/23
05/24
ESSENTIAL, NCT03627403: Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Checkmark Data of reduced spleen volume from ESSENTIAL trial for myelofibrosis
Nov 2022 - Nov 2022: Data of reduced spleen volume from ESSENTIAL trial for myelofibrosis
Checkmark Data from ESSENTIAL trial for myelofibrosis
Nov 2021 - Nov 2021: Data from ESSENTIAL trial for myelofibrosis
Checkmark New interim data from ESSENTIAL trial in previously treated myelofibrosis at ASH 2021
More
Active, not recruiting
2
17
US
Selinexor
University of Utah, Karyopharm Therapeutics Inc
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
08/23
03/25
NCT04854096: Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Terminated
2
7
Europe, US, RoW
NS-018, Best Available Therapy
NS Pharma, Inc., Nippon Shinyaku Co., Ltd.
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
05/24
05/24
ChiCTR2100045795: A non-comparative, open, phase II study of ruxolitinib in polycythemia vera subjects who are resistant to or intolerant of hydroxyurea or Interferon alpha

Recruiting
2
60
 
Take ruxolitinib orally
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Novartis Pharma Co., Ltd.
Polycythemia vera (PV)
 
 
NCT04878003: Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Recruiting
2
52
Europe, US, RoW
KRT-232, TL-895
Kartos Therapeutics, Inc.
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
05/24
10/25
NCT05467800: Study of Canakinumab in Patients With Myelofibrosis

Recruiting
2
26
US
Canakinumab
John Mascarenhas
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF
06/24
12/24
NCT05031897: Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

Recruiting
2
67
US
Hematopoietic Cell Transplantation, HCT, Hematopoietic Stem Cell Infusion, Hematopoietic Stem Cell Transplantation, HSCT, Stem Cell Transplant, Mycophenolate Mofetil, Tacrolimus, Cyclophosphamide, Total-Body Irradiation, Donor Lymphocyte Infusion, Fludarabine, Melphalan
Thomas Jefferson University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndromes, Myelofibrosis, Myeloid Leukemia, Myeloid Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Polycythemia Vera, Small Lymphocytic Lymphoma
10/24
10/24
NCT04262141: IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Active, not recruiting
2
4
US
IMG-7289, IMG7289, IMG 7289
Terrence J Bradley, MD, Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Essential Thrombocythemia, Polycythemia Vera
10/24
10/25
NCT04282187: Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Recruiting
2
25
US
Decitabine, 127716, 2''-Deoxy-5-azacytidine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Ruxolitinib, 941678-49-5, INCB-18424, Jakafi, Oral JAK Inhibitor INCB18424, Fedratinib, 936091-26-8, SAR302503, TG101348, Questionnaire Administration, Pacritinib, 937272-79-2, Oral JAK2 Inhibitor SB1518, SB 1518, SB-1518, SB1518
University of Washington
Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
11/26
11/26
NCT04517851: Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Active, not recruiting
2
15
US
Elotuzumab, BMS-901608, Empliciti, HuLuc-63, HuLuc63, PDL-063, PDL063, Questionnaire Administration
M.D. Anderson Cancer Center
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
12/24
12/24
ChiCTR2200064247: Efficacy and Safety of Low-dose Ruxoltinib in Patients with Lower and Intermediate Risk Polycythemia Vera ---a Single Arm, Exploratory and Prospective Study

Not yet recruiting
2
30
 
ruxoltinib
The Forth Affiliated Hospital Zhejiang University School of Medicine; The Forth Affiliated Hospital Zhejiang University School of Medicine, self-financing
Polycythemia Vera
 
 
NCT05143957 / 2021-003704-40: A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Recruiting
2
60
Europe, Canada, US, RoW
sapablursen, ISIS 702843, IONIS-TMPRSS6-LRx
Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc.
Phlebotomy Dependent Polycythemia Vera
01/25
12/25
MK-3543-004, NCT05558696: A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera

Active, not recruiting
2
20
Europe, US, RoW
bomedemstat, MK-3543, IMG-7289
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Polycythemia Vera
03/25
03/25
NCT05835466: Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Recruiting
2
26
US
reparixin
Icahn School of Medicine at Mount Sinai, Dompé Farmaceutici S.p.A
Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF)
03/25
03/26
NCI-2013-00704, NCT01787487: Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Recruiting
2
125
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Laboratory Biomarker Analysis, Ruxolitinib Phosphate, INCB-18424 Phosphate, Jakafi
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
04/25
04/25
REVIVE, NCT04057040: Hepcidin Mimetic in Patients With Polycythemia Vera

Hourglass Jan 2023 - Mar 2023 : Top-line data from REVIVE trial in patients with polycythemia vera
Active, not recruiting
2
80
US, RoW
PTG-300, Placebo
Protagonist Therapeutics, Inc.
Polycythemia Vera
10/25
01/26
NCT06063486: Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Recruiting
2
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Curcumin/ Demethoxycurcumin/Bisdemethoxycurcumin-containing Supplement, Curcumin C3 Complex, Piperine Extract (Standardized), Bioperine, Standardized Piperine Extract, Placebo Administration, Sugar pills, Questionnaire Administration
University of Southern California, National Cancer Institute (NCI)
Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelofibrosis, Polycythemia Vera
03/26
03/27
NCT03441113 / 2017-004350-42: Extended Access of Momelotinib in Adults With Myelofibrosis

Active, not recruiting
2
237
Europe, Canada, US, RoW
MMB, GS-0387, CYT387
GlaxoSmithKline
Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
12/26
12/26
Ruxo-BEAT, NCT02577926: The Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Active, not recruiting
2
207
Europe
Ruxolitinib, Study drug, Jakavi, BAT, Control Treatment
RWTH Aachen University, Novartis Pharmaceuticals
Polycythemia Vera (PV), Essential Thrombocythemia (ET)
12/27
12/28
PV, NCT05870475: Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant

Recruiting
2
94
RoW
Ruxolitinib, RUX, Pegylated interferon α-2b, PEG IFNα-2b
Institute of Hematology & Blood Diseases Hospital
Polycythemia Vera
03/28
05/28
NCT04485260 / 2019-004554-29: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Recruiting
1b/2
36
Europe, US, RoW
KRT-232, Ruxolitinib, Jakafi, Jakavi
Kartos Therapeutics, Inc.
Myelofibrosis
10/22
10/24
NCT04446650: A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Active, not recruiting
1/2
31
Japan
Fedratinib
Celgene
Primary Myelofibrosis
10/23
06/25
NCI-2019-03712, NCT03878199: Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Recruiting
1/2
47
US
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT, Stem Cell Transplantation, Allogeneic, Liposome-encapsulated Daunorubicin-Cytarabine, CPX-351, Cytarabine-Daunorubicin Liposome for Injection, Daunorubicin and Cytarabine (Liposomal), Liposomal AraC-Daunorubicin CPX-351, Liposomal Cytarabine-Daunorubicin, Liposome-encapsulated Combination of Daunorubicin and Cytarabine, Vyxeos, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424
Ohio State University Comprehensive Cancer Center, Incyte Corporation, Jazz Pharmaceuticals
Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia
12/24
12/24
NCI-2018-03465, NCT03862157: Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting
1/2
40
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, Onureg, U-18496, Vidaza, Pevonedistat, MLN4924, Nedd8-Activating Enzyme Inhibitor MLN4924, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Overt Primary Myelofibrosis, Polycythemia Vera, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Prefibrotic/Early Primary Myelofibrosis
01/25
01/25
LIMBER, NCT04455841: INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Recruiting
1/2
206
Europe, Canada, Japan, US
INCB000928, ruxolitinib
Incyte Corporation
Anemia, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
11/25
06/26
NCT05123365: An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Recruiting
1/2
27
US
N-Acetylcysteine, N-AC
University of California, Irvine
Myeloproliferative Neoplasm, MPN, Essential Thrombocythemia, Polycythemia Vera, Myelofibrosis
07/25
11/26
NCT05320198: Study of DISC-0974 in Participants With Myelofibrosis and Anemia

Recruiting
1/2
56
US
DISC-0974
Disc Medicine, Inc
Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
10/24
10/24
SANRECO, NCT05499013: Study to Assess SLN124 in Patients With Polycythemia Vera

Recruiting
1/2
65
Europe, US, RoW
SLN124, Placebo
Silence Therapeutics plc
Polycythemia Vera
12/24
06/25
PXS5505-MF-101, NCT04676529: Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Recruiting
1/2
39
US, RoW
PXS-5505
Syntara, Parexel
Myelofibrosis
08/25
08/25
NCT01727102: Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

Active, not recruiting
1
42
US
sunitinib malate, SU11248, sunitinib, Sutent, pharmacological study, pharmacological studies, laboratory biomarker analysis
National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Langerhans Cell Histiocytosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Aggressive NK-cell Leukemia, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Malignancies, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, HIV Infection, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Mast Cell Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Osteolytic Lesions of Multiple Myeloma, Peripheral T-cell Lymphoma, Plasma Cell Neoplasm, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Renal Cell Cancer, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
05/13
 
NCT00588991: Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Active, not recruiting
1
12
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Laboratory Biomarker Analysis, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Potactasol, SKF S-104864-A, Topotec, Topotecan HCl, topotecan hydrochloride (oral), Veliparib, ABT-888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Polycythemia Vera, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
02/14
03/25
NCT04896112: A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Withdrawn
1
93
US
LNK01002, LNK-1000318
Lynk Pharmaceuticals Co., Ltd
Acute Myeloid Leukemia, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
10/22
10/22
NCT02493530: TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Completed
1
60
US
TGR-1202, ruxolitinib, Jakafi
Vanderbilt-Ingram Cancer Center
Myelofibrosis, Polycythemia Vera
03/23
05/24
NCT05279001: A Safety and Tolerability Study of Jaktinib

Recruiting
1
26
US
Jaktinib Hydrochloride Tablet
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Myelofibrosis
05/25
11/25
PPMX-T003-CT102, NCT05074550: Safety Evaluation Study for Patients With Polycythemia Vera

Recruiting
1
6
Japan
PPMX-T003
Perseus Proteomics Inc.
Polycythemia Vera
08/23
03/24
NCT01588015: Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Completed
1
36
US
tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Promyelocytic Leukemia (M3), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cytomegalovirus Infection, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extramedullary Plasmacytoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Isolated Plasmacytoma of Bone, Monoclonal Gammopathy of Undetermined Significance, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Peripheral T-cell Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Primary Myelofibrosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Multiple Myeloma, Stage I Small Lymphocytic Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Small Lymphocytic Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
02/24
02/24
NCT06218628: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Recruiting
1
24
US
Talazoparib, talzenna, pacritinib, vonjo
Fox Chase Cancer Center
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia, Polycythemia Vera, Essential Thrombocytosis
08/29
08/30
NCT03972943: CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia

Terminated
1
8
US
Continuous Positive Airway Pressure, Continuous positive airway pressure (CPAP), CPAP, Patient Observation, Active Surveillance, deferred therapy, expectant management, observation, Watchful Waiting, Questionnaire Administration
University of Utah, National Cancer Institute (NCI)
CALR Gene Mutation, Essential Thrombocythemia, JAK2 Gene Mutation, MPL Gene Mutation, Obstructive Sleep Apnea Syndrome, Polycythemia Vera
07/23
07/23
GLB-001-02, NCT06378437: A Study of GLB-001 in Patients With Myeloid Malignancies

Recruiting
1
108
RoW
GLB-001, GLB-C183-A-2
Hangzhou GluBio Pharmaceutical Co., Ltd.
Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy
12/26
12/27
LIMBER, NCT04279847: Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Jul 2023 - Dec 2023: Data from LIMBER trial in combination with ruxolitinib for myelofibrosis
Checkmark Data from LIMBER trial for myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from LIMBER trial for myelofibrosis at ASH 2022
Recruiting
1
216
Europe, Canada, Japan, US
INCB057643, Ruxolitinib
Incyte Corporation
Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia)
11/24
12/24
NCT05714072: A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Recruiting
1
18
US
Ruxolitinib, Abemaciclib
Memorial Sloan Kettering Cancer Center, Eli Lilly and Company, Incyte Corporation
Myelofibrosis Due to and Following Polycythemia Vera
01/25
01/25
NCT06371573: Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms

Completed
N/A
45
Europe
ULTRASOUND EXAM AND MRI SCAN
Federico II University
Myeloproliferative Neoplasm, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic/Early Primary Myelofibrosis
01/24
03/24
PV-ARC, NCT06134102: Clinical and Laboratory Characteristics of Polycythemia Vera

Recruiting
N/A
1000
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Polycythemia Vera
12/23
12/23
NCT05269771: MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Available
N/A
NA
Ruxolitinib, Jakavi
Novartis Pharmaceuticals
Polycythemia Vera
 
 
 

Download Options